Neurocrine Biosciences (NBIX) Net Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Net Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | -204.00 |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 666.00 |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 3,167.00 |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 240.00 |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | -1,956.00 |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | -1,144.00 |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 1,366.00 |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | -94.00 |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | -604.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -604.00 |
| Mar 31, 2026 | 4,252.00 |
| Dec 31, 2025 | -252.00 |
| Sep 30, 2025 | 870.00 |
| Jun 30, 2025 | 2,010.00 |
| Mar 31, 2025 | -310.00 |
| Dec 31, 2024 | 1,876.00 |
| Sep 30, 2024 | 1,326.00 |
| Jun 30, 2024 | -363.00 |
| Mar 31, 2024 | -514.00 |
| Dec 31, 2023 | -11,167.00 |
| Sep 30, 2023 | 3,894.00 |
| Jun 30, 2023 | -523.00 |
| Mar 31, 2023 | -3,399.00 |
| Dec 31, 2022 | 767.00 |
| Sep 30, 2022 | -656.00 |
| Jun 30, 2022 | -3,242.00 |
| Mar 31, 2022 | 7,825.00 |
| Dec 31, 2021 | -1,661.00 |
| Sep 30, 2021 | -2,585.00 |